DAFTAR PUSTAKA

Adikusuma. (2021). *Adikusuma, W., Irham, L.M., Chou, W.H., Wong, H.S.C., Mugiyanto, E., Ting, J., Perwitasari, D.A., Chang, W.P. and Chang, W.C. (2021) 'Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information', Frontiers in Immunolog.* 6.

Adikusuma. (2022). *Adikusuma, W., Chou, W.H., Lin, M.R., Ting, J., Irham, L.M., Perwitasari, D.A., Chang, W.P. and Chang, W.C. (2022) 'Identification of Druggable Genes for Asthma by Integra ted Genomic Network Analysis', Biomedicines , 10(1). Available at: https://doi.org/. 10*(1), 10010113.

Alawieh, A., Sabra, Z., Nokkari, A., El-Assaad, A., Mondello, S., Zaraket, F., … Kobeissy, F. H. (2014). Bioinformatics approach to understanding interacting pathways in neuropsychiatric disorders. *Methods in Molecular Biology*, *1168*, 157–172. https://doi.org/10.1007/978-1-4939-0847-9_9

Albertini, L., Siest, G., Jeannesson, E., & Visvikis-Siest, S. (2011). Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: Personalized cancer therapy. *Pharmacogenomics*, *12*(5), 681–691. https://doi.org/10.2217/pgs.10.178

Appendix. (2010). *Rome III Diagnostic criteria for functional gastrointestinal disorders*.

Apweiler, R., Martin, M. J., O'Donovan, C., Magrane, M., Alam-Faruque, Y., Antunes, R., … Zhang, J. (2011). Ongoing and future developments at the Universal Protein Resource. *Nucleic Acids Research*, *39*(SUPPL. 1), 214–219. https://doi.org/10.1093/nar/gkq1020

Beghi, E., Antozzi, C., Batocchi, A. P., Cornelio, F., Cosi, V., Evoli, A., … Zarrelli, M. (1991). Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients. *Journal of the Neurological Sciences*, *106*(2), 213–220. https://doi.org/10.1016/0022-510X(91)90260-E

Berdigaliyev, N., & Aljofan, M. (2020). An overview of drug discovery and development. *Future Medicinal Chemistry*, *12*(10), 939–947. https://doi.org/10.4155/fmc-2019-0307

Buniello, A., Macarthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., … Parkinson, H. (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Research*, *47*(D1), D1005–D1012. https://doi.org/10.1093/nar/gky1120

Durães, F., Pinto, M., & Sousa, E. (2018). Old drugs as new treatments for neurodegenerative diseases. *Pharmaceuticals*, *11*(2), 1–21. https://doi.org/10.3390/ph11020044

Freshour, S. L., Kiwala, S., Cotto, K. C., Coffman, A. C., McMichael, J. F., Song, J. J., … Wagner, A. H. (2021). Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. *Nucleic Acids Research*, *49*(D1), D1144–D1151. https://doi.org/10.1093/nar/gkaa1084

Ghatak, S., Muthukumaran, R. B., & Nachimuthu, S. K. (2013). A simple method of genomic DNA extraction from human samples for PCR-RFLP analysis. *Journal of Biomolecular Techniques*, *24*(4), 224–231. https://doi.org/10.7171/jbt.13-2404-001

Gilhus, N. E., & Verschuuren, J. J. (2015). Myasthenia gravis: Subgroup classification and therapeutic strategies. *The Lancet Neurology*, *14*(10), 1023–1036. https://doi.org/10.1016/S1474-4422(15)00145-3

Gunji, K., Skolnick, C., Bednarczuk, T., Benes, S., Ackrell, B. A. C., Cochran, B., … Wall, J. R. (1998). Eye muscle antibodies in patients with ocular myasthenia gravis: Possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. *Clinical Immunology and Immunopathology*, *87*(3), 276–281. https://doi.org/10.1006/clin.1998.4536

Hanataka. (2005). *Clinical Pharmacokineties of paravastatin mecanism of pharmacokineties events 397-412*. *20*(5), 40–43. Retrieved from https://books.google.co.id/books?id=D9_YDwAAQBAJ&pg=PA369&lpg=PA369&dq=Prawirohardjo,+Sarwono.+2010.+Buku+Acuan+Nasional+Pelayanan+Kesehatan++Maternal+dan+Neonatal.+Jakarta+:+PT+Bina+Pustaka+Sarwono+Prawirohardjo.&source=bl&ots=riWNmMFyEq&sig=ACfU3U0HyN3I

Heather, J. M., & Chain, B. (2016). The sequence of sequencers: The history of sequencing DNA. *Genomics*, *107*(1), 1–8. https://doi.org/10.1016/j.ygeno.2015.11.003

Hu, X., Jia, T., Zhang, X., Wu, C., Zhang, Y., Chen, J., Guan, X., Shi, L., Lu, C.Y. and Nie, X. (2022) 'Clinical Pharmacists' Involvement in Pharmacogenomics Testing and Related Services in China', *Journal of Personalized Medicine*, 12(8), p. 1267. Available at: https://doi.org/10.3390/jpm12081267.

Irham, L. M., Adikusuma, W., & Perwitasari, D. A. (2022). Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach. *Biochemistry and Biophysics Reports*, *32*(August), 101334. https://doi.org/10.1016/j.bbrep.2022.101334

Irham, L. M., Chou, W. H., Calkins, M. J., Adikusuma, W., Hsieh, S. L., & Chang, W. C. (2020). Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population cohorts from multiple continents. *Biochemical and Biophysical Research Communications*, *529*(2), 263–269. https://doi.org/10.1016/j.bbrc.2020.05.179

Irham, L. M., Wong, H. S. C., Chou, W. H., Adikusuma, W., Mugiyanto, E., Huang, W. C., & Chang, W. C. (2020). Integration of genetic variants and gene network for drug repurposing in colorectal cancer. *Pharmacological Research*, *161*, 105203. https://doi.org/10.1016/j.phrs.2020.105203

Kakoulidou, M., Bjelak, S., Pirskanen, R., & Lefvert, A. K. (2007). A clinical and immunological study of a myasthenia gravis patient treated with infliximab. *Acta Neurologica Scandinavica*, *115*(4), 279–283. https://doi.org/10.1111/j.1600-0404.2006.00778.x

Keesey, J. C. (2004). Clinical evaluation and management of myasthenia gravis. *Muscle and Nerve*, *29*(4), 484–505. https://doi.org/10.1002/mus.20030

Kerty, E., Elsais, A., Argov, Z., Evoli, A., & Gilhus, N. E. (2014). EFNS/ENS Guidelines for the treatment of ocular myasthenia. *European Journal of Neurology*, *21*(5), 687–693. https://doi.org/10.1111/ene.12359

Kitts, A., Phan, L., Ward, M. and Holmes, J. B. (2014). (2014). *'The Database of*

Short Genetic Variation (dbSNP). The NCBI Handbook [Internet]', (Md). 2014.

Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023). Drug Repurposing: An Effective Tool in Modern Drug Discovery. *Russian Journal of Bioorganic Chemistry*, *49*(2), 157–166. https://doi.org/10.1134/S1068162023020139

Lesmana, M. H. S., Le, N. Q. K., Chiu, W. C., Chung, K. H., Wang, C. Y., Irham, L. M., & Chung, M. H. (2022). Genomic-Analysis-Oriented Drug Repurposing in the Search for Novel Antidepressants. *Biomedicines*, *10*(8), 1–16. https://doi.org/10.3390/biomedicines10081947

Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., & Zhang, B. (2019). WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Research*, *47*(W1), W199–W205. https://doi.org/10.1093/nar/gkz401

Liu, Y., Chen, S., Wang, Y., Zhang, Z., Zhang, H., Wang, Z., … Zhang, P. (2024). Dexamethasone improves thymoma-associated myasthenia gravis via the AKT-mTOR pathway. *Naunyn-Schmiedeberg's Archives of Pharmacology*, *397*(2), 817–828. https://doi.org/10.1007/s00210-023-02641-z

Low, S. K., Zembutsu, H., & Nakamura, Y. (2018). Breast cancer: The translation of big genomic data to cancer precision medicine. *Cancer Science*, *109*(3), 497–506. https://doi.org/10.1111/cas.13463

Meriggioli, M. N., & Sanders, D. B. (2004). *Myasthenia Gravis : Diagnosis*.

NHGRI. (2020). *NHGRI (2020) Genome-Wide Association Studies Fact Sheet , www.genome.gov . Available at: https://www.genome.gov/about-genomics/factsheets/Genome-Wide-Association- Studies-Fact-Sheet (Accessed: 23 June 2022).* (June), 2022.

Nicholson. (2006). *The Chemistry of Polymers 3rd Editon*.

NINDS. (2023). *National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet Accessed 3 Juli 2023. https://www.ninds.nih.gov/myasthenia-gravis-fact-sheet)..* 2023.

Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., … Plenge, R. M. (2014). Genetics of rheumatoid arthritis contributes to biology and drug

discovery. *Nature*, *506*(7488), 376–381. https://doi.org/10.1038/nature12873

Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019). Drug repurposing: a promising tool to accelerate the drug discovery process. *Drug Discovery Today*, *24*(10), 2076–2085. https://doi.org/10.1016/j.drudis.2019.06.014

Peragallo, J. H., Bitrian, E., Kupersmith, M. J., Zimprich, F., Whittaker, T. J., Lee, M. S., & Bruce, B. B. (2016). Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. *Journal of Neuro-Ophthalmology*, *36*(1), 29–32. https://doi.org/10.1097/WNO.0000000000000276

Philips, L. (2003). The epidemiology of Miasthenya Gravis. *Annals of the New York Academy of Sciences*, *988*(1), 407–412. Retrieved from https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1254.053

Pizzolato, K., Thacker, D., Toro-Pagán, N. Del, Hanna, A., Turgeon, J., Amin, N.S. and Michaud, V. (2022) 'Integrating Pharmacogenomic Results and Drug-Induced Phenoconversion Concepts while Conducting a Medication Safety Review Process', *Annals of Case Reports*, 7(2). Available at: https://doi.org/10.29011/2574-7754.100817

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., … Pirmohamed, M. (2018). Drug repurposing: Progress, challenges and recommendations. *Nature Reviews Drug Discovery*, *18*(1), 41–58. https://doi.org/10.1038/nrd.2018.168

Renton, A. E., Pliner, H. A., Provenzano, C., Evoli, A., Ricciardi, R., Nalls, M. A., … Traynor, B. J. (2015). A genome-wide association study of myasthenia gravis. *JAMA Neurology*, *72*(4), 396–404. https://doi.org/10.1001/jamaneurol.2014.4103

Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G. (2021). Drug Repurposing for Rare Diseases. *Trends in Pharmacological Sciences*, *42*(4), 255–267. https://doi.org/10.1016/j.tips.2021.01.003

Sahai, S., Adams, M., & Kamat, D. (2016). A diagnostic approach to autoimmune disorders: Clinical manifestations: Part 1. *Pediatric Annals*, *45*(6), e223–e229. https://doi.org/10.3928/00904481-20160422-01

Salari, N., Fatahi, B., Bartina, Y., Kazeminia, M., Fatahian, R., Mohammadi, P., … Mohammadi, M. (2021). Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. *Journal of Translational Medicine*, *19*(1), 1–23. https://doi.org/10.1186/s12967-021-03185-7

Sandag, G. A., & Taju, S. W. (2019). Bioinformatics Tools for Data Processing and Prediction of Protein Function. *CogITo Smart Journal*, *4*(2), 305–315. https://doi.org/10.31154/cogito.v4i2.137.305-315

Schultz, A., Saville, B. R., Marsh, J. A., & Snelling, T. L. (2019). An introduction to clinical trial design. *Paediatric Respiratory Reviews*, *32*(xxxx), 30–35. https://doi.org/10.1016/j.prrv.2019.06.002

Shah, A.H., Suter, R., Gudoor, P., Doucet-O'hare, T.T., Stathias, V., Cajigas, I., De La Fuente, M., Govindarajan, V., Morell, A.A., Eichberg, D.G., Luther, E., Lu, V.M., Heiss, J., Komotar, R.J., Ivan, M.E., Schurer, S., Gilbert, M.R. and Ayad, N.G. (2022) 'A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines', *Neuro-Oncology Advances*, 4(1). Available at: https://doi.org/10.1093/noajnl/vdab192.

Shah, R.R. and Smith, R.L. (2015) 'Addressing phenoconversion: the Achilles' heel of personalized medicine', *British Journal of Clinical Pharmacology*, 79(2), pp. 222–240. Available at: https://doi.org/10.1111/bcp.12441.

Thomas. (2017). The Genotype-Tissue Expression (GTEx) project. *Nature Genetics*, *45*(6), 580–585. https://doi.org/10.1038/ng.2653

Toro-Pagán, D., Marie, N., Matos, A., Thacker, D., Turgeon, J., Amin, N.S. and Michaud, V. (2021) 'Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report', *Medicina*, 57(9), p. 955. Available at: https://doi.org/10.3390/medicina57090955.

Wishart D, K. C. (2006). *DrugBank : Acetaminophen [Internet]*. *100*, 77–82. Retrieved from http://www.springer.com/series/15440%0Apapers://ae99785b-2213-416d-

aa7e-3a12880cc9b9/Paper/p18311

Yang, J., Wu, J., Han, T., Lu, H., Li, F., Li, L., … Hou, Z. (2023). Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: A bibliometric study. *Medicine (United States)*, *102*(24), E34002. https://doi.org/10.1097/MD.0000000000034002

Yang, W., He, X., He, C., Peng, L., Xing, S., Li, D., … Yuan, D. (2021). Impact of ESR1 Polymorphisms on Risk of Breast Cancer in the Chinese Han Population. *Clinical Breast Cancer*, *21*(3), e235–e242. https://doi.org/10.1016/j.clbc.2020.10.003

Zhang, F., Hammack, C., Ogden, S. C., Cheng, Y., Lee, E. M., Wen, Z., … Jin, P. (2016). Molecular signatures associated with ZIKV exposure in human cortical neural progenitors. *Nucleic Acids Research*, *44*(18), 8610–8620. https://doi.org/10.1093/nar/gkw765

Zhou, X., Iversen, E. S., & Parmigiani, G. (2005). Classification of missense mutations of disease genes. *Journal of the American Statistical Association*, *100*(469), 51–60. https://doi.org/10.1198/016214504000001817